Amarin Corp Plc (AMRN)

[Mr Stockboy]

One of 2023's Biggest BO Opportunities: "Investing in Amarin NOW, could return a 5-10x even greater multiple in just 1-2 years"

At $1.86/share, an investment of $100,000 offers an exponential return as hedge funds and investors scramble where to put their money.

The stock which once hit $26/share still has its eye of the life extension lifeline afforded by Vascepa/Vazcepa's unique properties. With the new BOD being steered by Sarissa Capital's Alex Denner, a major shareholder, the opportunity for the beaten down stock may be one of the hottest investment opportunities in a very uncertain global market. Vascepa/Vazcepa in its first life cycle (an enterprise drug) already holds a $3B annual opportunity which when exploited by big pharmas' deep pockets could easily result in 1-2 decades of a new mechanism extending healthy-heart life and mitigating against cardio vascular disease (CVD). The drug's unique molecule has already been shown in multiple studies to reverse arteriosclerosis including life-advancing anti-inflammatory properties. Like the entry of statins decades before, Vascepa/Vazcepa proven through clinical studies not only targets CVD, but is being explored in Alzheimer's and other diseases including Covid-19 and deadly viruses. Investors will want to get in sooner rather than later as news of the Sarissa regime is laser-focused on selling the company with a sense of true urgency.